20:19 EDT Cathie Wood’s ARK Investment bought 363.2K shares of Recursion Pharmaceuticals
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RXRX:
- Recursion Pharmaceuticals announces full enrollment of Phase 2 SYCAMORE trial
- Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
- Recursion to Participate in Upcoming Investor Conferences
- Altitude Lab Relocates to Gateway’s BioHive Hub
- Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer